Patients should avoid high concentrations of antifungal cream or contraceptive jelly, and should not douche prior to time of collection.
Collect
Cervical, anal, or vaginal specimen with brush or spatula from ThinPrep kit and place in PreservCyt Media
Minimum Volume
***This test only to be used with Anal or Vaginal Specimens***
For Cervical or Endocervical specimens, please order HPV PANEL LAB00809
Specimen Preparation
Transport original ThinPrep or briefly vortex and transfer 1 mL to an Aptima Specimen Transfer Tube (ARUP supply #42711). Available online through eSupply using ARUP Connect ™ or contact ARUP Client Services at 800-522-2787. To reduce the potential for contamination, ThinPrep specimens should be poured off, using sterile technique, into the Aptima Specimen Transfer Tube prior to cytology testing.
FDA-approved test for routine cervical cancer screening in combination with cervical cytology (pap smear) in individuals 30 years or older with a cervix. Follow-up test for abnormal cytology results in individuals 21 years or older with a cervix. Genotyping is performed to assess the presence or absence of high-risk HPV genotypes 16, 18, and/or 45, only as a follow-up to an Aptima HPV assay positive result.
Performed
Sun-Sat
Reported
1-5 days
Methodology
Qualitative Nucleic Acid Amplification (NAA)
Reference Interval
Negative
Interpretive Data
This test detects E6/E7 viral messenger RNA of 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) associated with cervical cancer and its precursor lesions. This test does not discriminate between the 14 high-risk HPV types. Sensitivity may be affected by specimen collection methods, stage of infection, and the presence of interfering substances. Results should be interpreted in conjunction with other available laboratory and clinical data. A negative high-risk HPV result does not exclude the presence of other high-risk HPV types.
HPV testing should not be used for screening or management of atypical squamous cells of undetermined significance (ASCUS) in women under age 21.
If Human Papillomavirus (HPV), High Risk is positive, then HPV genotypes 16, 18/45 will be added. Additional charges apply.
CPT Codes
87624; if reflexed, add 87625
LCHG
60102112
Performing Lab
ARUP Laboratories
Collection
Patient Preparation
Patients should avoid high concentrations of antifungal cream or contraceptive jelly, and should not douche prior to time of collection.
Collect
Cervical, anal, or vaginal specimen with brush or spatula from ThinPrep kit and place in PreservCyt Media
Minimum Volume
***This test only to be used with Anal or Vaginal Specimens***
For Cervical or Endocervical specimens, please order HPV PANEL LAB00809
Specimen Preparation
Transport original ThinPrep or briefly vortex and transfer 1 mL to an Aptima Specimen Transfer Tube (ARUP supply #42711). Available online through eSupply using ARUP Connect ™ or contact ARUP Client Services at 800-522-2787. To reduce the potential for contamination, ThinPrep specimens should be poured off, using sterile technique, into the Aptima Specimen Transfer Tube prior to cytology testing.
FDA-approved test for routine cervical cancer screening in combination with cervical cytology (pap smear) in individuals 30 years or older with a cervix. Follow-up test for abnormal cytology results in individuals 21 years or older with a cervix. Genotyping is performed to assess the presence or absence of high-risk HPV genotypes 16, 18, and/or 45, only as a follow-up to an Aptima HPV assay positive result.
Performance
Performed
Sun-Sat
Reported
1-5 days
Result Interpretation
Methodology
Qualitative Nucleic Acid Amplification (NAA)
Reference Interval
Negative
Interpretive Data
This test detects E6/E7 viral messenger RNA of 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) associated with cervical cancer and its precursor lesions. This test does not discriminate between the 14 high-risk HPV types. Sensitivity may be affected by specimen collection methods, stage of infection, and the presence of interfering substances. Results should be interpreted in conjunction with other available laboratory and clinical data. A negative high-risk HPV result does not exclude the presence of other high-risk HPV types.
HPV testing should not be used for screening or management of atypical squamous cells of undetermined significance (ASCUS) in women under age 21.
If Human Papillomavirus (HPV), High Risk is positive, then HPV genotypes 16, 18/45 will be added. Additional charges apply.
Laboratories.